Novel LC–MS Assays Impacting CYP and Transporter Drug–Drug Interaction Evaluations

References

• US FDA . In Vitro Metabolism- and Transporter-Mediated Drug–Drug Interaction Studies. Guidance for Industry (2017). www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM581965.pdf.
   Google Scholar
• US FDA . FDA (2010) Guidance for Industry M3(R2). Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (2010). www.fda.gov/downloads/drugs/guidances/ucm073246.pdf.
   Google Scholar
• Tweedie D , PolliJW, BerglundEGet al. Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium. Clin. Pharmacol. Ther.94 (1), 113–125 (2013).
   PubMed Web of Science ®Google Scholar
• Ronaldson PT , BauerB, El-KattanAF, ShenH, SalphatiL, LouieSW. Highlights from the American Association of Pharmaceutical Scientists/International Transporter Consortium Joint Workshop on drug transporters in absorption, distribution, metabolism, and excretion: from the bench to the bedside – clinical pharmacology considerations. Clin. Pharmacol. Ther.100 (5), 419–422 (2016).
   PubMed Web of Science ®Google Scholar
• Huang SM , ZhangL, GiacominiKM. The International Transporter Consortium: a collaborative group of scientists from academia, industry, and the FDA. Clin. Pharmacol. Ther.87 (1), 32–36 (2010).
   PubMed Web of Science ®Google Scholar
• Rendic S . Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev.34 (1–2), 83–448 (2002).
   PubMed Web of Science ®Google Scholar
• Rendic S , GuengerichFP. Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Curr. Drug Metab.11 (1), 4–84 (2010).
   PubMed Web of Science ®Google Scholar
• Yu J , ZhouZ, Tay-SontheimerJ, LevyRH, Ragueneau-MajlessiI. Risk of clinically relevant pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and drug administration between 2013 and 2016. Drug Metab. Dispos. doi:10.1124/dmd.117.078691 (2018) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Yan Z , CaldwellGW. The current status of time dependent CYP inhibition assay and in silico drug-drug interaction predictions. Curr. Top. Med. Chem.12 (11), 1291–1297 (2012).
   PubMed Web of Science ®Google Scholar
• Zientek M , YoudimK. Simultaneous determination of multiple CYP inhibition constants using a cocktail-probe approach. Methods Mol. Biol.987, 11–23 (2013).
   PubMedGoogle Scholar
• Volpe DA , BalimanePV. Application of in vitro CYP and transporter assays to predict clinical drug-drug interactions. Bioanalysis10 (9), 619–623 (2018).
   PubMed Web of Science ®Google Scholar
• Ramanathan R , MckenzieDL, TugnaitM, SiebenalerK. Application of semi-automated metabolite identification software in the drug discovery process for rapid identification of metabolites and the cytochrome P450 enzymes responsible for their formation. J. Pharm. Biomed. Anal.28 (5), 945–951 (2002).
   PubMed Web of Science ®Google Scholar
• Nielsen LM , HolmNB, Leth-PetersenS, KristensenJL, OlsenL, LinnetK. Characterization of the hepatic cytochrome P450 enzymes involved in the metabolism of 25I-NBOMe and 25I-NBOH. Drug Test. Anal.9 (5), 671–679 (2017).
   PubMed Web of Science ®Google Scholar
• Zhang L , ReynoldsKS, ZhaoP, HuangSM. Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicol. Appl. Pharmacol.243 (2), 134–145 (2010).
   PubMed Web of Science ®Google Scholar
• Huang SM , TempleR, ThrockmortonDC, LeskoLJ. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin. Pharmacol. Ther.81 (2), 298–304 (2007).
   PubMed Web of Science ®Google Scholar
• Ramanathan R , GhosalA, RamanathanL, ComstockK, ShenH, RamanathanDM. HPLC-HRMS with polarity switching for increasing throughput of human in vitro cocktail drug-drug interaction assay. Bioanalysis10 (9), 677–690 (2018).
   Web of Science ®Google Scholar
• Vaidyanathan J , YoshidaK, AryaV, ZhangL. Comparing various in vitro prediction criteria to assess the potential of a new molecular entity to inhibit organic anion transporting polypeptide 1B1. J. Clin. Pharmacol.56 (Suppl. 7), S59–S72 (2016).
   PubMedGoogle Scholar
• Tsuruya Y , KatoK, SanoYet al. Investigation of endogenous compounds applicable to drug-drug interaction studies involving the renal organic anion transporters, OAT1 and OAT3, in humans. Drug Metab. Dispos.44 (12), 1925–1933 (2016).
   PubMed Web of Science ®Google Scholar
• Rodrigues AD , TaskarKS, KusuharaH, SugiyamaY. Endogenous probes for drug transporters: balancing vision with reality. Clin. Pharmacol. Ther.103 (3), 434–448 (2017).
   PubMed Web of Science ®Google Scholar
• Ito S , KusuharaH, KumagaiYet al. N-methylnicotinamide is an endogenous probe for evaluation of drug-drug interactions involving multidrug and toxin extrusions (MATE1 and MATE2-K). Clin. Pharmacol. Ther.92 (5), 635–641 (2012).
   PubMed Web of Science ®Google Scholar
• Lee SC , AryaV, YangX, VolpeDA, ZhangL. Evaluation of transporters in drug development: Current status and contemporary issues. Adv. Drug Deliv. Rev.116, 100–118 (2017).
   PubMed Web of Science ®Google Scholar
• Rodrigues AD . Endogenous probes for human liver organic anion transporting polypeptides (OATPs): the Intersection of Bioanalytical and ADME science. Bioanalysis10 (9), 615–618 (2018).
   PubMed Web of Science ®Google Scholar
• Shen H . A pharmaceutical industry perspective on transporter and CYP mediated drug-drug interactions: kidney transporter biomarkers. Bioanalysis10 (9), 625–631 (2018).
   PubMed Web of Science ®Google Scholar
• Abe K , KonakaR. Quantification of urinary porphyrins by liquid chromatography after oxidation of porphyrinogens. Clin. Chem.35 (8), 1619–1622 (1989).
   PubMed Web of Science ®Google Scholar
• Bozek P , HuttaM, HrivnakovaB. Rapid analysis of porphyrins at low ng/l and microg/l levels in human urine by a gradient liquid chromatography method using octadecylsilica monolithic columns. J. Chromatogr. A1084 (1–2), 24–32 (2005).
   PubMed Web of Science ®Google Scholar
• Respaud R , Benz-De BretagneI, BlascoH, HulotJS, LechatP, Le GuellecC. Quantification of coproporphyrin isomers I and III in urine by HPLC and determination of their ratio for investigations of multidrug resistance protein 2 (MRP2) function in humans. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.877 (30), 3893–3898 (2009).
   PubMed Web of Science ®Google Scholar
• Jacob K , DossMO. Composition of urinary coproporphyrin isomers I-IV in human porphyrias. Eur. J. Clin. Chem. Clin. Biochem.31 (10), 617–624 (1993).
   PubMedGoogle Scholar
• Jacob K , EgelerE, GrossU, DossMO. Investigations on the formation of urinary coproporphyrin isomers I-IV in 5-aminolevulinic acid dehydratase deficiency porphyria, acute lead intoxication and after oral 5-aminolevulinic acid loading. Clin. Biochem.32 (2), 119–123 (1999).
   PubMed Web of Science ®Google Scholar
• To-Figueras J , OzallaD, MateuCH. Long-standing changes in the urinary profile of porphyrin isomers after clinical remission of porphyria cutanea tarda. Ann. Clin. Lab. Sci.33 (3), 251–256 (2003).
   PubMed Web of Science ®Google Scholar
• Cohen C , KirschRE, MooreMR. Porphobilinogen deaminase and the synthesis of porphyrin isomers in the Dubin-Johnson syndrome. S. Afr. Med. J.70 (1), 36–39 (1986).
   PubMed Web of Science ®Google Scholar
• Ramanathan R , King-AhmadAJ, HollimanCL, RodriguesAD. A highly selective and sensitive LC-MS/HRMS assay for quantifying coproporphyrins as organic anion-transporting peptide biomarkers. Bioanalysis9 (22), 1787–1806 (2017).
   PubMed Web of Science ®Google Scholar
• Shen H , DaiJ, LiuTet al. Coproporphyrins I and III as functional markers of OATP1B activity: in vitro and in vivo evaluation in preclinical species. J. Pharmacol. Exp. Ther.357 (2), 382–393 (2016).
   PubMed Web of Science ®Google Scholar
• Bednarczyk D , BoiselleC. Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III. Xenobiotica46 (5), 457–466 (2016).
   PubMed Web of Science ®Google Scholar
• Shen H , SuH, LiuTet al. Evaluation of rosuvastatin as an organic anion transporting polypeptide (OATP) probe substrate: in vitro transport and in vivo disposition in cynomolgus monkeys. J. Pharmacol. Exp. Ther.353 (2), 380–391 (2015).
   PubMed Web of Science ®Google Scholar
• Rodrigues AC , PerinPM, PurimSGet al. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int. J. Mol. Sci.12 (9), 5815–5827 (2011).
   PubMed Web of Science ®Google Scholar
• Njumbe Ediage E , DillenL, VromanAet al. Development of an LC–MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug–drug interactions. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.1073, 80–89 (2018).
   PubMed Web of Science ®Google Scholar
• King-Ahmad A , ClemensS, RamanathanRet al. A fully automated and validated human plasma LC–MS/MS assay for endogenous OATP biomarkers coproporphyrin-I and coproporphyrin III. Bioanalysis10 (9), 665–675 (2018).
   Web of Science ®Google Scholar
• Kandoussi H , ZengJ, ShahKet al. UHPLC–MS/MS bioanalysis of human plasma coproporphyrins as potential biomarkers for OATP-mediated drug interactions. Bioanalysis10 (9), 691–702 (2018).
   PubMed Web of Science ®Google Scholar
• Mazzacuva F , MillsP, MillsKet al. Identification of novel bile acids as biomarkers for the early diagnosis of Niemann-Pick C disease. FEBS Lett.590 (11), 1651–1662 (2016).
   PubMed Web of Science ®Google Scholar
• Rago B , TierneyB, RodriguesD, HollimanC, RamanathanR. A multiplex HRMS assay for quantifying selected human plasma bile acids as candidate OATP biomarkers. Bioanalysis10 (9), 633–645 (2018).
   PubMed Web of Science ®Google Scholar
• Luo L , KayJ, ZhangYet al. LC–MS/MS assay for N1-methylnicotinamide in humans, an endogenous probe for renal transporters. Bioanalysis10 (9), 673–689 (2018).
   PubMed Web of Science ®Google Scholar
• Ramanathan R , JosephsJL, JemalM, ArnoldM, HumphreysWG. Novel MS solutions inspired by MIST. Bioanalysis2 (7), 1291–1313 (2010).
   PubMed Web of Science ®Google Scholar
• Takahashi RH , KhojastehC, WrightM, HopC, MaS. Mixed matrix method provides a reliable metabolite exposure comparison for assessment of metabolites in safety testing (MIST). Drug Metab. Lett.11 (1), 21–28 (2017).
   PubMedGoogle Scholar